Given that first-line treatment for SCLC typically includes chemotherapy, and that corticosteroids are commonly used in clinical practice and have been reported to impair antitumor immune responses, particularly at high doses [32–34], we investigated whether these treatments affect IFITM3 expression. The gene discussed is IFITM3; the disease is small cell lung carcinoma.